Simplify CNS Drug Development with Integrated Solutions

National stakeholders meet at the French Residence in Stockholm yesterday for a roundtable aimed at turning strategic dialogue in life science into concrete directions for Europe’s innovation capacity.

The company has submitted an application for approval (BLA) to the US Food and Drug Administration for its biosimilar candidate to LUCENTIS (ranibizumab).

Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.

Once a fragmented landscape of strong research but limited cohesion, Stockholm’s life science ecosystem is now accelerating toward a more integrated future – a shift that Stockholm Science City’s CEO Ylva Williams has helped drive over nearly two decades.

The US‑based company has debuted in combined seed and Series A financing to advance a portfolio of mid‑stage neurology and neuropsychiatry drugs in‑licensed from Eisai and Hansoh.

The US company has closed an upsized, oversubscribed Series B to advance its optogenetic gene therapy pipeline for blinding retinal diseases with Novo Holdings reinforcing a strong Nordic investment footprint in late‑stage ophthalmology.

Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.